CA3064132C - Fatty acid derivatives and their use - Google Patents
Fatty acid derivatives and their use Download PDFInfo
- Publication number
- CA3064132C CA3064132C CA3064132A CA3064132A CA3064132C CA 3064132 C CA3064132 C CA 3064132C CA 3064132 A CA3064132 A CA 3064132A CA 3064132 A CA3064132 A CA 3064132A CA 3064132 C CA3064132 C CA 3064132C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- stereoisomer
- pharmaceutically acceptable
- tautomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
- C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
- C07C33/025—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond
- C07C33/03—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond in beta-position, e.g. allyl alcohol, methallyl alcohol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529846P | 2017-07-07 | 2017-07-07 | |
| US62/529,846 | 2017-07-07 | ||
| PCT/US2018/041086 WO2019010414A1 (en) | 2017-07-07 | 2018-07-06 | FATTY ACID DERIVATIVES AND USE THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3064132A1 CA3064132A1 (en) | 2019-01-10 |
| CA3064132C true CA3064132C (en) | 2024-06-04 |
Family
ID=63036390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3064132A Active CA3064132C (en) | 2017-07-07 | 2018-07-06 | Fatty acid derivatives and their use |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11555021B2 (enExample) |
| EP (1) | EP3649115B1 (enExample) |
| JP (1) | JP7234151B2 (enExample) |
| KR (1) | KR102725883B1 (enExample) |
| CN (1) | CN110869354A (enExample) |
| AU (1) | AU2018297192B2 (enExample) |
| CA (1) | CA3064132C (enExample) |
| MX (1) | MX391168B (enExample) |
| WO (1) | WO2019010414A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018070164B1 (pt) | 2016-04-01 | 2022-09-27 | Sony Corporation Of America | Corantes diméricos ou poliméricos ultrabrilhantes |
| CN109153860B (zh) | 2016-04-06 | 2021-04-23 | 索尼公司 | 具有间隔连接体基团的超高亮二聚体或聚合物染料 |
| WO2018022925A1 (en) | 2016-07-29 | 2018-02-01 | Sony Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| US12290571B2 (en) | 2017-10-05 | 2025-05-06 | Sony Group Corporation | Programmable dendritic drugs |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| US12076407B2 (en) | 2018-01-12 | 2024-09-03 | Sony Group Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| EP3737417B1 (en) | 2018-01-12 | 2025-08-27 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| KR102864292B1 (ko) | 2018-03-21 | 2025-09-26 | 소니그룹주식회사 | 링커 군을 갖는 중합체성 텐덤 염료 |
| JP7580689B2 (ja) | 2018-06-27 | 2024-11-12 | ソニーグループ株式会社 | デオキシリボースを含むリンカー基を有するポリマー色素 |
| US12578342B2 (en) | 2018-07-13 | 2026-03-17 | Sony Group Corporation | Polymeric dyes having a backbone comprising organophosphate units |
| EP3861074A2 (en) | 2019-09-26 | 2021-08-11 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
| EP4038081A1 (en) | 2019-09-30 | 2022-08-10 | Sony Group Corporation | Nucleotide probes |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| CN113121475B (zh) * | 2021-03-30 | 2022-12-02 | 香港科技大学深圳研究院 | 不饱和脂肪酸类化合物及其制备方法和应用 |
| CN113620923B (zh) * | 2021-07-16 | 2023-03-14 | 扬州工业职业技术学院 | 一种低温电解液添加剂的制备方法及应用 |
| CN115073295B (zh) * | 2022-07-21 | 2023-12-26 | 山东大学 | 马齿苋中不饱和脂肪酸及其提取分离方法和应用 |
| WO2024237316A1 (ja) * | 2023-05-16 | 2024-11-21 | 国立大学法人東京大学 | エポキシ化不飽和脂肪酸の皮膚線維化改善作用 |
| EP4613730A1 (en) * | 2024-03-05 | 2025-09-10 | Centre National de la Recherche Scientifique | Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055613A (en) * | 1988-02-18 | 1991-10-08 | G. D. Searle & Co. | Metabolites of pentanedioic acid derivatives |
| ATE168372T1 (de) * | 1993-03-29 | 1998-08-15 | Hsc Res Dev Lp | Hepoxilin analoga verwendbar als entzündungshemmende mittel |
| IL121165A0 (en) * | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| US20020037876A1 (en) * | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| BR0012447A (pt) * | 1999-07-15 | 2002-04-02 | Lilly Co Eli | Análogos de pseudomicina de cadeia lateral de n-acila |
| US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
| DE102004037118A1 (de) | 2004-07-30 | 2006-03-23 | Degussa Ag | Titandioxid enthaltende Dispersion |
| WO2006106438A2 (en) | 2005-01-11 | 2006-10-12 | Evolva Sa | Modulators of ppar activity |
| JP5337479B2 (ja) | 2005-05-04 | 2013-11-06 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 新規化合物 |
| IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
| JP5552121B2 (ja) * | 2008-09-04 | 2014-07-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のインドリジン阻害剤 |
| WO2013157926A1 (en) | 2012-04-19 | 2013-10-24 | Nyken Holding B.V. | Geranyl geranyl acetone analogs and uses thereof |
| JP6160375B2 (ja) | 2013-09-06 | 2017-07-12 | ブラザー工業株式会社 | 画像記録装置 |
-
2018
- 2018-07-06 MX MX2019015730A patent/MX391168B/es unknown
- 2018-07-06 US US16/622,697 patent/US11555021B2/en active Active
- 2018-07-06 EP EP18746415.1A patent/EP3649115B1/en active Active
- 2018-07-06 JP JP2019572570A patent/JP7234151B2/ja active Active
- 2018-07-06 WO PCT/US2018/041086 patent/WO2019010414A1/en not_active Ceased
- 2018-07-06 CA CA3064132A patent/CA3064132C/en active Active
- 2018-07-06 CN CN201880045287.6A patent/CN110869354A/zh active Pending
- 2018-07-06 AU AU2018297192A patent/AU2018297192B2/en active Active
- 2018-07-06 KR KR1020207003568A patent/KR102725883B1/ko active Active
-
2022
- 2022-04-12 US US17/718,965 patent/US12479812B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3649115B1 (en) | 2024-09-04 |
| KR102725883B1 (ko) | 2024-11-01 |
| EP3649115A1 (en) | 2020-05-13 |
| AU2018297192B2 (en) | 2022-02-17 |
| US20220274940A1 (en) | 2022-09-01 |
| JP7234151B2 (ja) | 2023-03-07 |
| AU2018297192A1 (en) | 2019-12-19 |
| US20210139440A1 (en) | 2021-05-13 |
| CN110869354A (zh) | 2020-03-06 |
| MX391168B (es) | 2025-03-21 |
| WO2019010414A1 (en) | 2019-01-10 |
| US12479812B2 (en) | 2025-11-25 |
| JP2020526505A (ja) | 2020-08-31 |
| KR20200027545A (ko) | 2020-03-12 |
| CA3064132A1 (en) | 2019-01-10 |
| EP3649115C0 (en) | 2024-09-04 |
| US11555021B2 (en) | 2023-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12479812B2 (en) | Fatty acid derivatives and their use | |
| ES2792676T3 (es) | Compuestos del ácido 14-hidroxi-docosahexaenoico | |
| CN115427396B (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
| WO2007142158A1 (ja) | ９，１０－セコプレグナン誘導体及び医薬 | |
| US20050234025A1 (en) | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof | |
| DE69320352T2 (de) | Piperidinylamide, sulfonamide und sulfoxamide als inhibitoren der cholesterin biosynthese | |
| JPH01249733A (ja) | ペンタン二酸誘導体の代謝物質 | |
| US20260022089A1 (en) | Quinone-derived compounds and use thereof against leishmania spp | |
| JP5125101B2 (ja) | ９，１０−セコプレグナン誘導体及び医薬 | |
| US20100172957A1 (en) | Eflucimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals | |
| WO2003002585A1 (fr) | Derives de [4-(4-cyanobenzoyl)phenyl]glycopyranoside, utilisation en tant que medicament, procede d'obtention et compositions | |
| WO1992008712A1 (fr) | Derive de flavane ou son sel et nouveau procede de production | |
| WO2003002586A1 (fr) | Derives de [4-(4-cyanobenzoyl)phenyl]glycofuranoside, utilisation en tant que medicament, procede d'obtention et compositions pharmaceutiques les contenant | |
| JPH05279298A (ja) | カルボン酸誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220225 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260626 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260626 |